An Israeli study showed that the South African mutation of the Coronavirus is able to “penetrate” the “Pfizer-Biontech” vaccine to some extent, despite its low prevalence in Israel.
The study compared about 400 people who tested positive for the virus 14 days or more after they received a dose or two of the vaccine, and a group of other infected people who were not immunized with the vaccine.
The study, which was conducted by Tel Aviv University in cooperation with “Clalit”, the largest healthcare institution in Israel, stated that it detected the South African surge in approximately one percent of the total cases studied.
She explained that “the prevalence of the mutation among patients who received two doses of the vaccine was eight times higher than among unvaccinated patients, at a rate of 5.4 to 0.7 percent.”
The researchers said, “This indicates that the vaccine is less effective with the South African mutation compared to the mother virus and the British mutation.”
“We detected a disproportionately higher rate of the South African mutation among the infected people who received the second dose of the vaccine, compared to the group of unvaccinated individuals,” said researcher Addy Stern. “This means that the South African mutation is able, to some extent, to penetrate the protection of the vaccine.”
The researchers cautioned, however, that the study was conducted on a small group of individuals with the mutation due to its scarcity in Israel.